Analysis of the ATR-Chk1 and ATM-Chk2 pathways in male breast cancer revealed the prognostic significance of ATR expression

[1]  V. Speirs,et al.  Association between AXL, Hippo Transducers, and Survival Outcomes in Male Breast Cancer , 2017, Journal of cellular physiology.

[2]  E. Gallo,et al.  DNA damage repair and survival outcomes in advanced gastric cancer patients treated with first‐line chemotherapy , 2017, International journal of cancer.

[3]  V. Speirs,et al.  HMG-CoAR expression in male breast cancer: relationship with hormone receptors, Hippo transducers and survival outcomes , 2016, Scientific Reports.

[4]  V. Speirs,et al.  The Hippo transducers TAZ/YAP and their target CTGF in male breast cancer , 2016, Oncotarget.

[5]  Melissa P. Murray,et al.  The Genomic Landscape of Male Breast Cancers , 2016, Clinical Cancer Research.

[6]  L. Mariani,et al.  DNA Damage and Repair Biomarkers in Cervical Cancer Patients Treated with Neoadjuvant Chemotherapy: An Exploratory Analysis , 2016, PloS one.

[7]  I. Ellis,et al.  Chk1 phosphorylated at serine345 is a predictor of early local recurrence and radio‐resistance in breast cancer , 2016, Molecular oncology.

[8]  P. Jeggo,et al.  DNA repair, genome stability and cancer: a historical perspective , 2015, Nature Reviews Cancer.

[9]  I. Vitale,et al.  Predictive significance of DNA damage and repair biomarkers in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: An exploratory analysis , 2015, Oncotarget.

[10]  V. Speirs,et al.  Role of gonadotropin-releasing hormone analogues in metastatic male breast cancer: results from a pooled analysis , 2015, Journal of Hematology & Oncology.

[11]  A. Ryan,et al.  ATM and ATR as therapeutic targets in cancer. , 2015, Pharmacology & therapeutics.

[12]  A. Aguilera,et al.  Replication stress and cancer , 2015, Nature Reviews Cancer.

[13]  I. Vitale,et al.  Trial Watch: Targeting ATM–CHK2 and ATR–CHK1 pathways for anticancer therapy , 2015, Molecular & Cellular Oncology.

[14]  I. Ellis,et al.  Checkpoint kinase1 (CHK1) is an important biomarker in breast cancer having a role in chemotherapy response , 2015, British Journal of Cancer.

[15]  G. Ball,et al.  Targeting BRCA1‐BER deficient breast cancer by ATM or DNA‐PKcs blockade either alone or in combination with cisplatin for personalized therapy , 2015, Molecular oncology.

[16]  R. Maria,et al.  Antiandrogen therapy in metastatic male breast cancer: results from an updated analysis in an expanded case series , 2014, Breast Cancer Research and Treatment.

[17]  Timothy L. Scott,et al.  Repair of oxidative DNA damage and cancer: recent progress in DNA base excision repair. , 2014, Antioxidants & redox signaling.

[18]  P. C. de Witt Hamer,et al.  WEE1 inhibition and genomic instability in cancer. , 2013, Biochimica et biophysica acta.

[19]  M. Ringnér,et al.  The Landscape of Candidate Driver Genes Differs between Male and Female Breast Cancer , 2013, PloS one.

[20]  L. Zou,et al.  DNA damage sensing by the ATM and ATR kinases. , 2013, Cold Spring Harbor perspectives in biology.

[21]  S. Tomao,et al.  Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer , 2013, Breast Cancer Research and Treatment.

[22]  M. Bartucci,et al.  Checkpoint kinase 1 inhibitors for potentiating systemic anticancer therapy. , 2013, Cancer treatment reviews.

[23]  E. Winer,et al.  Male breast cancer: risk factors, biology, diagnosis, treatment, and survivorship. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  M. Dimopoulos,et al.  Aromatase inhibitors with or without gonadotropin-releasing hormone analogue in metastatic male breast cancer: a case series , 2013, British Journal of Cancer.

[25]  A. Pinder,et al.  A potent Chk1 inhibitor is selectively cytotoxic in melanomas with high levels of replicative stress , 2013, Oncogene.

[26]  G. Ball,et al.  A comparative biomarker study of 514 matched cases of male and female breast cancer reveals gender-specific biological differences , 2012, Breast Cancer Research and Treatment.

[27]  P. V. van Diest,et al.  Oncogene amplification in male breast cancer: analysis by multiplex ligation-dependent probe amplification , 2012, Breast Cancer Research and Treatment.

[28]  M. Ringnér,et al.  Gene expression profiling of primary male breast cancers reveals two unique subgroups and identifies N-acetyltransferase-1 (NAT1) as a novel prognostic biomarker , 2012, Breast Cancer Research.

[29]  M. Barbacid,et al.  Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors , 2011, Nature Structural &Molecular Biology.

[30]  M. Biffoni,et al.  Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy , 2011, Cell Death and Differentiation.

[31]  M. Ringnér,et al.  High-resolution genomic profiling of male breast cancer reveals differences hidden behind the similarities with female breast cancer , 2011, Breast Cancer Research and Treatment.

[32]  M. Gariboldi,et al.  Gene expression analysis reveals a different transcriptomic landscape in female and male breast cancer , 2011, Breast Cancer Research and Treatment.

[33]  G. Hortobagyi,et al.  Retrospective review of male breast cancer patients: analysis of tamoxifen-related side-effects. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  S. Elledge,et al.  The DNA damage response: making it safe to play with knives. , 2010, Molecular cell.

[35]  A. Italiano,et al.  Aromatase inhibition in male breast cancer patients: biological and clinical implications. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  J. Bergh,et al.  Multidisciplinary meeting on male breast cancer: summary and research recommendations. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  Philip S Rosenberg,et al.  Male breast cancer: a population-based comparison with female breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  Stefano Volinia,et al.  MicroRNA expression profiling of male breast cancer , 2009, Breast Cancer Research.

[39]  K. Cimprich,et al.  ATR: an essential regulator of genome integrity , 2008, Nature Reviews Molecular Cell Biology.

[40]  Jiri Bartek,et al.  Chk1 and Chk2 kinases in checkpoint control and cancer. , 2003, Cancer cell.

[41]  H. Dixon,et al.  Therapeutic Exploitation of Checkpoint Defects in Cancer Cells Lacking p53 Function , 2002, Cell cycle.

[42]  R. Bartsch,et al.  Fulvestrant and male breast cancer: a case series. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[43]  S. Costa,et al.  Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients , 2012, Breast Cancer Research and Treatment.